Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.5871
+0.0146 (2.55%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
2.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 37.65K | -93.87K | -71.37% |
| Dec 31, 2022 | 131.52K | 44.53K | 51.20% |
| Dec 31, 2021 | 86.99K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 939.93K | -92.30K | -8.94% |
| Dec 31, 2013 | 1.03M | -299.53K | -22.49% |
| Dec 31, 2012 | 1.33M | -112.69K | -7.80% |
| Dec 31, 2011 | 1.44M | 135.54K | 10.36% |
| Dec 31, 2010 | 1.31M | 667.63K | 104.11% |
| Dec 31, 2009 | 641.29K | 407.75K | 174.59% |
| Dec 31, 2008 | 233.54K | 100.45K | 75.48% |
| Dec 31, 2007 | 133.09K | 66.91K | 101.11% |
| Dec 31, 2006 | 66.18K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bio Green Med Solution | 1.53M |
| SciSparc | 856.00K |
| VivoSim Labs | 142.00K |
| Biodexa Pharmaceuticals | 104.90K |
| Azitra | 7.50K |
| Virax Biolabs Group | 2.99K |
OGEN News
- 5 weeks ago - Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - GlobeNewsWire
- 5 weeks ago - ORAGENICS PROVIDES INVESTOR UPDATE - GlobeNewsWire
- 7 weeks ago - Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - GlobeNewsWire
- 7 weeks ago - Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - GlobeNewsWire
- 2 months ago - Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002 - TheFly
- 2 months ago - Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewsWire
- 3 months ago - Oragenics receives audit opinion with going concern explanation - TheFly
- 3 months ago - Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewsWire